Our Focus: Best-in-Class, Oral Drugs for Inflammatory and Metabolic Diseases
ABP-671
Our Potent and Safe Gout Drug is Poised to Enter Phase 3 Trials in 2022
Hyperuricemia and Gout
Gout is caused by hyperuricemia (elevated uric acid in blood). The chronic condition, which affects 55 million people worldwide, results in uric acid crystals settling in joints producing severe pain, swelling and redness. Patients can experience debilitating acute gout attacks suddenly.
ABP-671 is an inhibitor of urate transporter (URAT1) proteins, which are involved in reabsorption of uric acid by the kidneys.
- First line monotherapy for all gout patients
- Easy-to-use once a day in an oral tablet
- More potent and effective in reducing sUA vs. current gout drugs.
- Superior safety profile compared to allopurinol/febuxostat
Additional indications for APB-671 may include kidney disease, hyperuricemia in cancer chemotherapy patients and refractory gout.
Total WW Gout Market (2019)
~USD 1.5 Billion (US ~75%)
Market Growth Rate (2015-19)
+5% Annually
APB-6061
Preparing to File IND Application for U.S. Clinical Trials of Treatment of NASH
Non-Alcoholic steatohepatis (NASH)
Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NASH causes the buildup of fat in liver cells resulting in inflammation and damage, which can lead to scarring of the liver, cirrhosis, liver cancer and liver transplant.
NAFLD is a global epidemic and likely to become the most common cause of liver disease worldwide in the next decade.
In preclinical studies, Atom Biosciences ABP-6061 demonstrated effectiveness in improving liver function measured by reduction in levels of liver enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT).
Atom Biosciences expects to file an investigational new drug application in the next 12 to 15 months to begin clinical trials in the U.S. for NASH. The company also plans to develop ABP-6061 for chronic persistent hepatitis. The global market for NASH treatments is expected to exceed $35 billion by 2030.